Mealey's (February 22, 2023, 2:14 PM EST) -- SAN FRANCISCO — A Ninth Circuit U.S. Court of Appeals panel on Feb. 21 found that a federal district court’s dismissal of shareholders’ claims against a manufacturer of products and services used in the study of health and disease and two of its senior executives who are alleged to have concealed that the company’s cytometry segment sales would not meet revenue expectations was proper because a lead plaintiff has failed to sufficiently plead that any of the alleged misstatements were actionable under federal securities law....